



DOI: 10.5137/1019-5149.JTN.17866-16.1

Received: 12.04.2016 / Accepted: 31.07.2016

Published Online: 22.08.2016

Turk Neurosurg 28(1):1-6, 2018

Original Investigation

# Retrospective Analysis of 449 Intracranial Meningioma Patients Operated Between 2007 and 2013 at a Single Institute

Emrah CELTIKCI<sup>1</sup>, A. Memduh KAYMAZ<sup>2</sup>, Gulsah AKGUL<sup>3</sup>, Burak KARAASLAN<sup>2</sup>, O. Hakan EMMEZ<sup>2</sup>, Alp BORCEK<sup>4</sup>

<sup>1</sup>Yildirim Beyazit University, Yenimahalle Research and Education Hospital, Department of Neurosurgery, Ankara, Turkey

<sup>2</sup>Gazi University, Faculty of Medicine, Department of Neurosurgery, Ankara, Turkey

<sup>3</sup>Yuksekk Ihtisas University, Faculty of Medicine, Department of Pathology, Ankara, Turkey

<sup>4</sup>Gazi University, Faculty of Medicine, Department of Neurosurgery, Division of Pediatric Neurosurgery, Ankara, Turkey

Early results of this manuscript was presented as an oral presentation in Turkish Language in April 2015 at the Turkish Neurosurgical Society's 29<sup>th</sup> Annual Congress, Antalya, Turkey.

## ABSTRACT

**AIM:** Meningioma literature has many large surgical case series, which have been references of text books and neurosurgical practice. Many of those series were published when stereotactic radiosurgery (SRS) was not so common or these series were in terms of World Health Organization (WHO) 2000 classification. In this study, we aimed to make an update to the current literature using WHO 2007 classification system.

**MATERIAL and METHODS:** Four hundred eighty-eight intracranial meningioma patients underwent open surgery in 2007-2013 and 449 of them were included in this study. All pathological specimens were re-evaluated in terms of WHO 2007 classification. All demographical and follow-up records and imaging archives were investigated by using our center's central automation system and National Central Population Management System. If records were not available or not adequate, investigators made phone calls to patients. Pediatric patients were excluded.

**RESULTS:** Three hundred twenty-six female (76.2%) and 123 male (27.4%) patients were analyzed. Their ages ranged from 18 to 84 years (mean=51.6±11.9 years). The most common subtype of meningioma was meningothelial meningioma (51.7%), followed by atypical meningioma (20.3%). WHO Grade I meningiomas had statistically random localization distribution, but WHO Grade II meningiomas were more common in the convexity, parasagittal and middle fossa. Younger age was found to be significantly related with tumor recurrence or progression. Seventy-three (16.2%) patients underwent SRS and 64 (14.2%) patients underwent adjuvant radiotherapy (ART) after surgery. Convexity localization was found to be associated with recurrence, mortality and higher WHO 2007 grade.

**CONCLUSION:** Convexity meningiomas are associated with recurrence, mortality and higher WHO 2007 grade. Convexity meningiomas should be totally resected in order to achieve maximum benefit from surgery,

**KEYWORDS:** Intracranial, Meningioma, Stereotactic radiosurgery, Pathology

**ABBREVIATIONS:** ART: Adjuvant radiotherapy, CNS: Central nervous system, CPA: Cerebellopontine angle, ICU: Intensive care unit, SRS: Stereotactic radiosurgery, VTE: Venous thromboembolism, WHO: World Health Organization.



Corresponding author: Emrah CELTIKCI

E-mail: drceltikci@gmail.com

## ■ INTRODUCTION

Meningiomas are neoplasms that originate from arachnoid cap cells. They are one of the most commonly diagnosed primary tumors of the central nervous system (CNS) (3,4,10,11,24,37,42,49). The World Health Organization (WHO) 2007 classification system classifies meningiomas into three grades, I-III, with 16 different variants or subtypes (30,36). Grade III meningiomas show a higher rate of recurrence and mortality compared with Grade I and II meningiomas (19,31,43,47,48).

However, decision making for this disease not only depends on its WHO Grade. Variables including patient characteristics, tumor localization, grade, surgical approach, intraoperative challenges and especially the follow-up period determine outcome. In the literature, there is a female predominance in adulthood meningiomas and a variable ratio of WHO grade II meningiomas (4,8,17,18,23,29,33,46). There is a known relatively high risk of postoperative venous thromboembolism (VTE) (1,6,9,12,20,21,26,28,34). Also there are large series investigating the relationship between age, sex, pathological subtype and location (8,18,42,46,49). However, there is a lack of large series including multiple variables that can affect the outcome and their intricate relations.

We retrospectively analyzed data of 449 adult intracranial meningioma patients operated between 2007 and 2013 at a tertiary center in Turkey.

## ■ MATERIAL and METHODS

This study includes intracranial meningioma cases that underwent surgery between January 2007 and December 2013 at Gazi University, Faculty of Medicine, Department of Neurosurgery. Patient charts, surgical records and follow-up notes were reviewed and analyzed. Gazi University, Faculty of Medicine, Patient Registry Software and National Population Management Software were used to achieve required data. If there was a need for additional data, telephone calls were made. Data collected at the last follow-up visit were used. Inclusion criteria were 18 years of age or older, no previous surgery for intracranial meningioma, and single meningioma. Patients with inadequate data, younger than 18 years, with previous surgery or stereotactic radiosurgery (SRS), and who had only SRS, multiple meningioma, or any type of neurofibromatosis were excluded from the study due to their possible effects on statistics. We also did not investigate surgical approaches as this study not focused on the effects of surgical approaches.

All patients stayed at intensive care unit (ICU) for at least one night after surgery. If there was no disabling functional loss, all patients were started on oral feeding and mobilization in the first morning after surgery. We used low molecular weight heparin 48 hours after the operation if patient was unable to mobilize well or was bedridden. Also compression stockings were routinely used in every patient until discharge from hospital.

All pathological specimens were re-evaluated by a single pathologist. Pathological classifications referred to the 2007 WHO Classification of Tumors of the Central Nervous System (30).

Parameters were: age, sex, tumor location, pathological subtype, Simpson grade of surgical excision, tumor recurrence or progression during follow-up, VTE in the follow-up period, adjuvant radiotherapy (ART) during follow-up, SRS during follow-up and survival time.

Tumor locations were classified as parasagittal, convexity, sphenoid, sellar/parasellar, posterior fossa, olfactory groove/frontobasal, middle fossa/Meckel's Cave, tentorial, peritorcular and intraventricular.

Descriptive data were presented as mean and standard deviation. Fisher's Exact Test, one way variance analysis, and t-test for 2 independent variables were used for group comparisons. Survival was estimated by the Kaplan-Meier method, and the log-rank test was used for comparisons.

The institutional ethics committee approved the study and the study protocol.

## ■ RESULTS

### Descriptive Data

Between January 2007 and December 2013, 488 adult patients underwent surgery for intracranial meningioma. Four hundred forty-nine patients' data met the inclusion criteria. Mean follow-up period was  $53.42 \pm 6.53$  months. Mean age was  $51.67 \pm 11.96$  years (min 18, max 84 years). There were 123 (24.6%) male and 326 (65.3%) female. Distribution of localizations and pathological subtypes are summarized in Table I. Three hundred thirty-six (74.8%) patients were WHO Grade 1, 100 (22.3%) patients were grade 2, and 12 (2.7%) patients were grade 3. One patient had sclerosing subtype which is outside the grading system.

Surgical resections were done as follows: 72 (16%) Simpson Grade 1, 277 (61.6%) Simpson Grade 2, and 100 (22.2%) Simpson grade 3 and 4.

VTE was seen in 21 (4.6%) patients and tumor recurrence or progression was seen in 58 (12.9%) patients in follow-up period.

Seventy-three (16.2%) patients underwent SRS and 64 (14.2%) patients underwent ART after surgery. There were 4 patients who underwent both ART and SRS. Three of them were WHO grade 2 atypical meningioma and 1 was WHO grade 3 anaplastic meningioma. All of those 4 patients underwent ART first, then underwent SRS because of tumor progression.

Forty-four (9.7%) patients died until the last follow-up date. Thirteen (29.5%) of those patients were never discharged from hospital after operation. Five of them died because of VTE and the other 8 died from other complications (cardiac and respiratory problems, infection etc.). After discharge, 4 of the remaining 31 patients died because of other malignancies.

**Table I:** Distribution of Tumor Locations and Histopathological Subtypes

Location	Pathology														Total	
	Meningothelial	Fibrous	Transitional	Psammomatous	Angiomatous	Microcystic	Secretory	Lymphoplasmacyte - Rich	Metaplastic	Clear cell	Chordoid	Atypical	Rhabdoid	Anaplastic		Sclerosing
Parasagittal	29	5	6	4	0	1	1	2	0	2	0	18	0	0	0	68
Convexity	49	5	7	7	7	2	4	1	0	3	1	37	1	8	0	132
Sphenoid	38	1	0	1	0	0	1	1	1	0	0	5	0	0	1	49
Sellar/Parasellar	28	0	2	3	1	0	0	0	0	0	0	2	0	0	0	36
Posterior Fossa	31	1	6	3	1	0	2	0	0	0	3	5	0	1	0	53
Olfactory Groove/ Frontobasal	10	0	1	0	2	0	0	0	0	0	0	6	0	1	0	20
Middle Fossa/Meckel's Cave	31	0	5	4	1	0	0	0	0	0	0	11	1	0	0	53
Tentorial	11	0	4	2	2	0	0	0	0	0	0	4	0	0	0	23
Peritorcular	5	0	4	1	0	0	0	0	0	0	0	3	0	0	0	13
Intraventricular	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	2
Total	232	12	37	25	14	3	8	4	1	5	4	91	2	10	1	449

A patient with transitional meningioma died because of colorectal cancer, a patient with meningothelial meningioma died because of myosarcoma, a patient with psammomatous meningioma died because of lung adenocarcinoma, and a patient with lymphoplasmacyte-rich meningioma died because of diffuse large B cell lymphoma. Sixteen of remaining 27 patients died related to neurological deterioration due to recurrence of high grade meningioma. All the remaining 11 patients died because of non-neurological reasons and all of them were elderly (>65 years).

### Group Comparisons

We found a relationship between WHO Grades and localizations. Results of Fischer's Test demonstrated that Grade 2 and 3 meningiomas were localized more commonly at the convexity ( $X^2=47.27$ ,  $p=0.009$ ).

There was no correlation between pathological subtypes and sex ( $X^2=12.037$ ,  $p=0.572$ ), and no correlation between pathological subtypes and Simpson Grade ( $p=0.256$ ). If we exclude meningiomas located at the convexity or parasagittally, the remaining patients' resection rates are 65.7% for Simpson Grade 2, 33.4% for Simpson Grade 3 & 4 and 0.8% for Simpson Grade 1.


There was no correlation between pathological subtypes and sex ( $X^2 = 12.037$ ,  $p=0.572$ ) and we found no correlation

between age and WHO 2007 grade. On the other hand, the mean age was younger in patients who experienced tumor recurrence or progression during follow up ( $p=0.025$ ) regardless of tumor grade. Also, the mean age was younger in patients who underwent SRS ( $p=0.001$ ).

There was a correlation between VTE and sex ( $X^2=4.531$ ,  $p=0.033$ ). The male gender was found as a risk factor for experiencing VTE. Elderly patients tended to experience VTE in follow-up period ( $t=-3.012$ ,  $p=0.003$ ) (Figure 1). We found no statistically significant correlation between VTE and other variables.

When we analyzed all pathological subtypes, the highest tumor recurrence/progression rates were found in anaplastic meningiomas (70%), followed by secretory meningiomas (25%), lymphoplasmacyte-rich meningiomas (25%) and atypical meningiomas (22%). However due to their low patient numbers, it is not possible to do a statistical decision about recurrence rates of secretory and lymphoplasmacyte-rich meningiomas. Among 58 patients who experienced tumor recurrence or progression, 7 patients (12%) were WHO grade 3, 20 patients (34.4%) were WHO grade 2, and 31 patients (53.4%) were WHO grade 1.

Overall and recurrence free survivals were significantly longer in patients with atypical meningioma than those with anaplastic meningioma; 157.1 versus 44.6 months and 121.9



**Figure 1:** Relationship between venous thromboembolism (VTE) and age (t – test for 2 independent variables;  $t = -3,012$ ,  $p=0.003$ ).

versus 26.3 months ( $p<0.001$ ). Also convexity localization was found to be related with higher mortality due to higher incidence of higher WHO grades. 18 of 44 patients who died in follow up (40.9%) had convexity meningiomas. Amongst this convexity - mortality group there was 14 Grade 2 or 3 meningiomas.

## DISCUSSION

Our study has similar findings with the literature including female predominance and age distribution (although we excluded the pediatric group)(4,8,17,18,23,35,37,42,46,49). In series of Wang et al. (46), there was a higher female: male ratio in WHO grade 2 and 3 meningiomas, but we found no difference in our series. Our conclusion is, even with pediatric patients or not, this age distribution is a classical characteristic of meningiomas.

VTE is still a risk for patients who underwent intracranial meningioma surgery and clinical incidences range up to 32% (1,6,9,12,20,21,26,28,34). In our series, 4.6% of patients experienced VTE and 5 patients died because of pulmonary embolism. Additionally, we found elderly age and male gender as risk factors for VTE during the follow-up period. In contrast to other series and our series, Hoefnagel et al. investigated the effects of the body mass index (BMI) on thromboembolic complications and found an increased risk in higher weighted patients (23). Effects of BMI on VTE risk is a well-considered study. However, it must be kept in mind if higher BMI patients are also lesser mobilizing ones or not. We concluded that preservation of motor functions and early mobilization after surgery is the key for decreasing VTE rates. Future studies based on calculating mobilization (by the help of new mobile technologies) can be planned to predict individual risk of VTE on meningioma patients.

We found that meningothelial (51.7%) and atypical (20.3%) meningiomas were the most common pathological subtypes

of meningiomas. There is an increasing trend to the frequency of Grade 2 meningiomas in literature as well as 26% and 30% (25,26). Our series has 22.3% Grade 2 patients. Also there are series in which Grade 2 & 3 percentage is approximately 10% (35).

In our series, tumor localization were; parasagittal, convexity, sphenoid, sellar/parasellar, posterior fossa, olfactory groove/frontobasal, middle fossa/Meckel's Cave, tentorial, peritortular and intraventricular. We classified localizations different than Al-Mefty's classification (15,27). Al-Mefty's classification is much more detailed and more applicable in prospective studies. However, our study is designed as a retrospective study based on clinical notes, surgical records, patients' cards and radiological images. One of the limitations of this study is being a retrospective study, so we tried to summarize and to fit localization classification for our retrospective study. We did not use localization terms as falcotentorium, tuberculum sellae, lateral and middle sphenoid wing, clinoidal, cavernous sinus, sphenoorbital, cerebellar convexity, cerebellopontine angle (CPA), clival and petroclival, temporal bone, foramen magnum, isolated ventricular and pineal region. Instead we used the term "tentorial meningioma" for all tentorium-related meningiomas, "sellar/parasellar" for all sellae and cavernous meningiomas, "sphenoidal" for all sphenoid-related meningiomas, "posterior fossa" for all cerebellar convexity, foramen magnum and CPA meningiomas and "intraventricular" for all ventricle-related meningiomas. In our series, convexity and parasagittal regions were the most common sites for meningioma growth (44.5%) which is similar with series of Wang et al. and Al-Mefty (15,16,46). Also, non-skull base localizations were found related with higher mortality and higher pathological grade similar with series of Kane et al. (25). Series of Cao et al. implies opposite of this finding, however, as we understand from their manuscript they analyzed just anaplastic subgroup, but not the distribution of other subtypes (7). Our conclusion, which is concordant with findings of Kane et al., is; non-skull base localization is a poor prognostic factor due to higher incidence of grade 2 and 3 meningiomas.

Even though non-skull base localizations are related with poor prognosis, it doesn't mean skull base and posterior fossa meningiomas are surgically easy to deal with. Skull base and posterior fossa are surgically challenging localizations for meningiomas and microsurgical resection of these tumors is frequently associated with new onset of neurological impairment (2,5,13,14,16,22,38-40,41,44,45). There are numerous series in literature, describing surgical approaches to skull base and posterior fossa, explaining challenging parts of those surgeries and neuro-functional results (2,5,14,16,22,38-40,41,44,45). However, many of those series were published when the SRS was not so common (32). In our series, nearly 52.1% of all meningiomas were located in the skull base or posterior fossa. As mentioned in the results section, those locations had relatively higher Simpson grades. As a referral SRS center (Leksell Gamma Knife Model 4C and Perfexion, Elekta), we already performed more than 6000 SRS procedures since 2004. This alternative choice gives chance of intraoperative decision making for total removal of skull base or posterior fossa tumors. Preservation of functional neurological status

and decreasing complication rates are very important instead of total removal of tumors. Our resection rates decrease in skull base, comparing to other localizations. In follow-up period, we performed SRS “where needed”. In 249 skull base and posterior fossa patient groups, only 63 patients (25%) underwent SRS (all Simpson grade 2 and higher) and analysis of those patients showed that 24 of them underwent SRS for tumor recurrence or progression in follow-up period (9.6% of all skull base and posterior fossa meningiomas). Remaining patients underwent postoperative adjuvant SRS. In the literature, total removal of basal meningiomas was achieved in 60-87.5% of the patients and 30-56% of the patients suffered complications (2,5,13,14,38-40,45). Our conclusion about SRS is: It is a good choice in meningioma management even post operatively or alone for functional preservation. Additionally, we concluded that SRS is the reason why our series has a relatively higher rate of grade 2 and 3 meningiomas. Convexity meningiomas are much more preferred for surgery by neurosurgeons instead of skull base meningiomas. As convexity is associated with recurrence and higher WHO 2007 grade, that’s why we have relatively more grade 2 and 3 meningioma patients.

## ■ CONCLUSION

Convexity meningiomas are associated with recurrence, mortality and higher WHO 2007 grade. To achieve maximum benefit from surgery, convexity meningiomas should be totally resected. Adjuvant therapies like SRS can be beneficial for meningiomas located in the skull base hence total resection of those meningiomas may cause functional loss and they tend to be more benign.

## ■ ACKNOWLEDGMENT

We thank Pinar Celtikci for her help in data collection, and we offer our respect to all our patients for letting us to learn from them.

## ■ REFERENCES

1. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G: Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med* 339:80–85, 1998
2. Arnautovic KI, Al Mefty O, Husain M: Ventral foramen magnum meningiomas. *J Neurosurg* 92:71–80, 2000
3. Backer-Grøndahl T, Thomas, Moen BH, Torp SH: The histopathological spectrum of human meningiomas. *Int J Clin Exp Pathol* 5:231-242, 2012
4. Bondy M, Ligon BL: Epidemiology and etiology of intracranial meningiomas: A review. *J Neurooncol* 29:197-205, 1996
5. Bricolo AP, Turazzi S, Talacchi A, Cristofori L: Microsurgical removal of petroclival meningiomas: A report of 33 patients. *Neurosurgery* 31:813–828, 1992
6. Browd SR, Ragel BT, Davis GE, Scott AM, Skalabrin EJ, Couldwell WT: Prophylaxis for deep venous thrombosis in neurosurgery: A review of the literature. *Neurosurg Focus* 17(4):1-6, 2004
7. Cao X, Hao S, Wu Z, Wang L, Jia G, Zhang L, Zhang J: Survival rates, prognostic factors and treatment of anaplastic meningiomas. *J Clin Neurosci* 22(5):828-833, 2015
8. Cea-Soriano L, Wallander MA, Garcia RL: Epidemiology of meningioma in the United Kingdom. *Neuroepidemiology* 39:27-34, 2012
9. Chan AT, Atiemo A, Diran LK, Licholai GP, Black PM, Creager MA, Goldhaber SZ: Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. *J Thromb Thrombolysis* 8(2):139–142, 1999
10. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT, Yang I: The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurg Focus* 30(5):E6, 2011
11. Coke CC, Corn BW, Werner-Wasik M, Xie Y, Curran WJ Jr: Atypical and malignant meningiomas: An outcome report of seventeen cases. *J Neurooncol* 39:65–70, 1998
12. Constantini S, Kornowski R, Pomeranz S, Rappaport ZH: Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors. *Acta Neurochir (Wien)* 109(3–4):93–97, 1991
13. Couldwell WT, Fukushima T, Giannotta SL, Weiss MH: Petroclival meningiomas: Surgical experience in 109 cases. *J Neurosurg* 84:20–28, 1996
14. De Jesus O, Sekhar LN, Parikh HK, Wright DC, Wagner DP: Long-term follow-up of patients with meningiomas involving the cavernous sinus: Recurrence, progression, and quality of life. *Neurosurgery* 39:915–919, 1996
15. DeMonte F, McDermott MW, Al-Mefty O, (eds). *Al-Mefty’s Meningioma*. New York/Stuttgart:Thieme, 2011
16. DeMonte F, Smith HK, Al Mefty O: Outcome of aggressive removal of cavernous sinus meningiomas. *J Neurosurg* 81:245–251, 1994
17. Dobs M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, Dexter M, Cook R: Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000–2008): Findings of a multicenter Australian study. *Surg Neurol Int* 2: 176, 2011
18. Dolecek TA, Propp JM, Stroup NE, Kruchko C: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. *Neuro-oncology* 14: v1-v49, 2012
19. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamarides M, Menei P, Deruty R, Moreau JJ, Fevre-Montange M, Guyotat J: WHO grade II and III meningiomas: A study of prognostic factors. *J Neurooncol* 95:367–375, 2009
20. Eisenring CV, Neidert MC, Sabanes Bove D, Held L, Sarnthein J, Krayenbuhl N: Reduction of thromboembolic events in meningioma surgery: A cohort study of 724 consecutive patients. *PLoS ONE* 8(11):e79170, 2013
21. Frim DM, Barker FG, Poletti CE, Hamilton AJ: Postoperative low-dose heparin decreases thromboembolic complications in neurosurgical patients. *Neurosurgery* 30(6):830–832, 1992

22. George B, Lot G, Boissonnet H: Meningioma of the foramen magnum: A series of 40 cases. *Surg Neurol* 47:371–379, 1997
23. Hoefnagel D, Kwee LE, van Putten EHP, Kros JM, Dirven CMF, Dammers R: The incidence of postoperative thromboembolic complications following surgical resection of intracranial meningioma. A retrospective study of a large single center patient cohort. *Clin Neurol Neurosurg* 123: 150-154, 2014
24. Jiang T, Tang GF, Lin Y, Peng XX, Zhang X, Zhai XW, Peng X, Yang JQ, Huang HE, Wu NF, Chen XJ, Xing HX, Su TY, Wang ZC: Prevalence estimates for primary brain tumors in China: A multi-center cross-sectional study. *Chin Med J* 124: 2578-2583, 2011
25. Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, Berger MS, Parsa AT: Anatomic location is a risk factor for atypical and malignant meningiomas. *Cancer* 117:1272-1278, 2011
26. Khaldi A, Helo N, Schneck MJ, Origitano TC: Venous thromboembolism: Deep venous thrombosis and pulmonary embolism in a neurosurgical population. *J Neurosurg* 114(1):40–46, 2011
27. Ko KW, Nam DH, Kong DS, Lee YI, Park K, Kim JH: Relationship between malignant subtypes of meningioma and clinical outcome. *J Clin Neurosci* 14:747–753, 2007
28. Levi AD, Wallace MC, Bernstein M, Walters BC: Venous thromboembolism after brain tumor surgery: A retrospective review. *Neurosurgery* 28(6):859–863, 1991
29. Li X, Zhao J: Intracranial meningiomas of childhood and adolescence: Report of 34 cases with follow-up. *Childs Nerv Syst* 25: 1411-1417, 2009
30. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* 114(2): 97-109, 2007
31. Mangubat EZ, Byrne RW: Major intratumoral hemorrhage of a petroclival atypical meningioma: Case report and review of literature. *Skull Base* 20:469–473, 2010
32. Marcus HJ, Price SJ, Wilby M, Santarius T, Kirillos RW: Radiotherapy as an adjuvant in the management of intracranial meningiomas: Are we practising evidence-based medicine? *Br J Neurosurg* 22:520–528, 2008
33. Menon G, Nair S, Sudhir J, Rao BR, Mathew A, Bahuleyan B: Childhood and adolescent meningiomas: A report of 38 cases and review of literature. *Acta Neurochir (Wien)* 151: 239-244, 2009
34. Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d’Azemar P, Buller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M: Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. *Thromb Haemost* 75(2):233–238, 1996
35. Ostrom QT, Gittleman NE, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. *Neuro-Oncology* 15 Suppl 2: ii1-ii56, 2013
36. Pearson BE, Markert JM, Fisher WS, Guthrie BL, Fiveash JB, Palmer CA, Riley K: Hitting a moving target: Evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria. A case series. *Neurosurg Focus* 24(5):E3, 2008
37. Rigau V, Zouaoui S, Mathieu-Daude H, Darlix A, Maran A, Tretarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, Costes V, Bauchet L: French brain tumor database: 5-year histological results on 25756 cases. *Brain Pathol* 21:633-644, 2011
38. Samii M, Carvalho GA, Tatagiba M, Matthies C: Surgical management of meningiomas originating in Meckel’s cave. *Neurosurgery* 41:767–774, 1997
39. Samii M, Klekamp J, Carvalho G: Surgical results for meningiomas of the craniocervical junction. *Neurosurgery* 39:1086–1094, 1996
40. Samii M, Tatagiba M: Experience with 36 surgical cases of petroclival meningiomas. *Acta Neurochir (Wien)* 118:27–32, 1992
41. Sekhar LN, Swamy NKS, Jaiswal V, Rubinstein E, Hirsch WE Jr, Wright DC: Surgical excision of meningiomas involving the clivus: Preoperative and intraoperative features as predictors of postoperative functional deterioration. *J Neurosurg* 81:860–868, 1994
42. Shibui S: The present status and trend of brain tumors based on the data of the Brain Tumor Registry of Japan. *Brain Nerve* 64: 286-290, 2012
43. Simpson D: The recurrence of intracranial meningiomas after surgical treatment. *J Neurol Neurosurg Psychiatry* 20:22–39, 1957
44. Spallone A, Makhmudov UB, Mukhamedjanov DJ, Tcherekajev VA: Petroclival meningioma. An attempt to define the role of skull base approaches in their surgical management. *Surg Neurol* 51:412–419, 1999
45. Thomas NW, King TT: Meningiomas of the cerebellopontine angle. A report of 41 cases. *Br J Neurosurg* 10:59–68, 1996
46. Wang DJ, Xie Q, Gong Y, Mao Y, Wang Y, Cheng HX, Zhong P, Che XM, Jiang CC, Huang FP, Zheng K, Li SQ, Bao WM, Yang BJ, Wu JS, Xie LQ, Zheng MZ, Tang HL, Zhu HD, Chen XC, Zhou LF: Histopathological classification and location of consecutively operated meningiomas at a single institution in China from 2001 to 2010. *Chin Med J* 126(3):488–493, 2013
47. Whittle IR, Smith C, Navoo P, Collie D: Meningiomas. *Lancet* 363(9420):1535–1543, 2004
48. Yew A, Gopen Q, Parsa AT, Yang I: The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurg Focus* 30:E6, 2011
49. Zouaoui S, Rigau V, Mathieu-Daude H, Darlix A, Bessaoud F, Fabbro-Peray P, Bauchet F, Kerr C, Fabbro M, Figarella-Branger D, Taillandier L, Duffau H, Trettare B, Bauchet L: French brain tumor database: General results on 40,000 cases, main current applications and future prospects. *Neurochirurgie* 58:4-13, 2012